786 - A Randomized Controlled Trial Comparing Six-Food Elimination Diet vs Topical Steroids in Inducing and Maintaining Remission of Pediatric Eosinophilic Esophagitis

2018 ◽  
Vol 154 (6) ◽  
pp. S-163-S-164
Author(s):  
Salvatore Oliva ◽  
Cosimo Ruggiero ◽  
Danilo Rossetti ◽  
Valeria Tinti ◽  
Licia Salimbene ◽  
...  
2018 ◽  
Vol 63 (9) ◽  
pp. 2381-2388 ◽  
Author(s):  
Craig C. Reed ◽  
Anca M. Safta ◽  
Shadi Qasem ◽  
M. Angie Almond ◽  
Evan S. Dellon ◽  
...  

2019 ◽  
Vol 57 (06) ◽  
pp. 745-752 ◽  
Author(s):  
Stephan Miehlke ◽  
Ulrike von Arnim ◽  
Christoph Schlag ◽  
Thomas Frieling ◽  
Ahmed Madisch ◽  
...  

Abstract Background Eosinophilic esophagitis (EoE) is an increasingly recognized immune-mediated esophageal disease and a common cause for dysphagia and food bolus obstruction. The aim of this study was to evaluate the current clinical management of EoE among adult gastroenterologists in Germany. Methods We performed a cross-sectional study of 1393 adult gastroenterologists using a questionnaire containing 22 questions to general, diagnostic, and therapeutic aspects of EoE. The self-administered online survey was conducted between November 2017 and February 2018. Data capture and analysis was performed using SurveyMonkey. Results The overall responder rate was 29.6 %. More than half of the responders (54.9 %) felt to observe a significant increase of EoE patients. The EREFS score was mostly either unknown (44.3 %) or not routinely used (52.2 %). If EoE was suspected, most responders obtained multiple esophageal biopsies (n = 3 – 4: 35.7 %; n > 4: 61.6 %). The preferred primary treatment was proton pump inhibitors (PPI) in 37.2 % and topical steroids in 35.0 % of responders. PPI regimens were highly diverse, with only half of responders using high-dose PPI regimens. Allergy testing was often initiated (always 25.4 %, sometimes 48.9 %). The most common dietary therapy was 6-food elimination diet (52 %), followed by allergy test-directed diets (16 %) and 2-food elimination diet (16.5 %). The majority of responders indicated a need for long-term treatment (i. e., 23 % of responders in > 50 % their patients and 47.7 % of responders in 25 – 50 % of their patients). Conclusions Among gastroenterologists in Germany, substantial variation in the adherence to published EoE guidelines appears to exist. This indicates the need for intensified education and national guidelines in order to optimize and harmonize the clinical management of EoE patients.


2021 ◽  
Vol 160 (6) ◽  
pp. S-109-S-110
Author(s):  
Kara Kliewer ◽  
Nirmala Gonsalves ◽  
Evan S. Dellon ◽  
David A. Katzka ◽  
Seema S. Aceves ◽  
...  

2021 ◽  
Author(s):  
Nicole Diane Hamburger ◽  
Michelle L. Goedken

BACKGROUND Lichen sclerosus is a chronic inflammatory autoimmune skin disease and the etiology is not well understood. It can affect the female vulvar genital region causing painful, pruritic symptoms that negatively impact a woman’s quality of life. The current primary treatment for vulvar lichen scleorsus (VLS) is topical steroids but a number of other treatments are being studied at this time. OBJECTIVE There are numerous recalcitrant VLS cases that require secondary forms of treatment. One of which is the use of fractional CO2 laser therapy, which functions by superficially vaporizing the epidermis creating a microablative effect while also inducing collagen remodeling within the dermis. This review aims to bring awareness to this secondary form of treatment for VLS. METHODS Four articles are reviewed that were published in the last year (2020-2021) evaluating the improvements in VLS symptoms after at least two treatments of fractionated CO2 laser therapy. RESULTS Three of the four articles included patients that suffered from previously treated VLS experiencing persistent symptoms. Only one of the studies was a randomized controlled trial. The follow-up time ranged from one month to sixteen months. Two studies showed statistically significant improvement in symptoms such as vaginal pain, itching, and dyspareunia. The other two studies reported improvement in these symptoms, however, the results were not statistically significant. Other symptoms noted to show improvement were erythema, leukoderma, and skin elasticity. After five to seven treatments with this CO2 laser, there was also a reduction in erosions and fissures as well as restoration of normal skin color and texture. Adverse events from this treatment included minor burning and blistering at the laser site. CONCLUSIONS While the recent published work suggests there may be a benefit to the use of fractionated CO2 laser therapy for recalcitrant VLS, only one of them was a randomized controlled trial. Future studies should be completed with this design. Until then, the treatment should follow guidelines with topical steroids being the primary form of management. CLINICALTRIAL none


Sign in / Sign up

Export Citation Format

Share Document